20/20 Biolabs Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
17.3%projected annual EPS growth
Analyst Coverage
1analyst covering
FY Revenue (est.)
$2.9Mnext fiscal year
FY EPS (est.)
-$0.42next fiscal year
Monitoring Framework
Key Performance Indicators
Multi-Cancer Early Detection (MCED) Revenue Growth Quarterly30.0%Target: At least 30% year-over-year growth for Q2 2026
Tested Firefighter Population Annually35KTarget: 35,000 tested by the end of 2026
Quarterly Revenue Quarterly353.4KTarget: Rebound from Q1 2026 decline
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Closing bid price below $1.00 for 30 consecutive business daysAction: Regain compliance by maintaining a closing bid price of at least $1.00 for at least 10 consecutive business days before January 13, 2027.
- Series E Preferred Stock ConversionsTrigger: Expiration of the 120-day standstill agreement with Streeterville Capital (effective July 16, 2026)Action: Monitor potential dilution and common share count increases from formula-based conversions.
- FDA Authorization and Medicare Reimbursement PathwayTrigger: Statutory pathway for Medicare reimbursement of FDA-authorized MCED blood tests beginning in 2028Action: Advance clinical evidence, real-world screening data, and obtain FDA authorization and CMS clinical appropriateness determination.
Research as of 24 Jul 2026